Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Multiple Myeloma 29Leukemia, Myeloid, Acute 14Recurrence 13Hodgkin Disease 12Lymphoma 11Neoplasms 10Breast Neoplasms 9Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, T-Cell, Cutaneous 6Sezary Syndrome 5Neoplasms, Plasma Cell 5Mycosis Fungoides 5Lymphoma, Mantle-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Waldenstrom Macroglobulinemia 4Neoplasm Metastasis 4Melanoma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Immunoblastic Lymphadenopathy 4Diffuse Intrinsic Pontine Glioma 4Advanced Solid Tumors 4Primary Myelofibrosis 3

Interventions

Cyclophosphamide 76fludarabine phosphate 41Filgrastim 38Peripheral Blood Stem Cell Transplantation 34Radiotherapy 33Cyclosporine 32Busulfan 31Etoposide 30Mycophenolic Acid 29Antilymphocyte Serum 28Whole-Body Irradiation 25Methotrexate 25Rituximab 22Melphalan 21Methylprednisolone 20Vincristine 17Tacrolimus 16Doxorubicin 16Cytarabine 16Cord Blood Stem Cell Transplantation 16Prednisone 15Thiotepa 10Granulocyte Colony-Stimulating Factor 9Carboplatin 8Leucovorin 7fludarabine 6aldesleukin 6Ifosfamide 6sargramostim 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Dendritic Cell Sarcoma, Interdigitating × Panobinostat × Clear all
NCT01282476 2017-05-09

Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
18 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡